BeOne Medicines Expands U.S. Cancer Access and Manufacturing
SAN CARLOS, Calif., August 31, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN CARLOS, Calif., August 31, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company,...
CAMBRIDGE, Mass., August 18, 2026 Amylyx Pharmaceuticals has announced the commencement of an underwritten public offering of $350.0 million...
SAN FRANCISCO, June 4 2026 Chai Discovery has announced a strategic license agreement with Pfizer that will enable the...
